Search Results - "Blanke, C"

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma by El-Khoueiry, A B, Rankin, C, Siegel, A B, Iqbal, S, Gong, I-Y, Micetich, K C, Kayaleh, O R, Lenz, H-J, Blanke, C D

“…Background: Gallbladder cancers and cholangiocarcinomas make up a heterogenous group of tumours with a poor prognosis in advanced stages. On the basis of…”
Get full text

Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance) by Cohen, R., Shi, Q., Meyers, J., Jin, Z., Svrcek, M., Fuchs, C., Couture, F., Kuebler, P., Ciombor, K.K., Bendell, J., De Jesus-Acosta, A., Kumar, P., Lewis, D., Tan, B., Bertagnolli, M.M., Philip, P., Blanke, C., O'Reilly, E.M., Shields, A., Meyerhardt, J.A.

“…In colon cancer, tumor deposits (TD) are considered in assigning prognosis and staging only in the absence of lymph node metastasis (i.e. stage III pN1c…”
Get full text

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer by Iqbal, S., Goldman, B., Fenoglio-Preiser, C.M., Lenz, H.J., Zhang, W., Danenberg, K.D., Shibata, S.I., Blanke, C.D.

“…Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2),…”
Get full text

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial by Gordon, M.A., Gundacker, H.M., Benedetti, J., Macdonald, J.S., Baranda, J.C., Levin, W.J., Blanke, C.D., Elatre, W., Weng, P., Zhou, J.Y., Lenz, H.J., Press, M.F.

“…Trastuzumab has been approved for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric carcinoma; however, relatively…”
Get full text

Medical-aid-in-dying use in the US Pacific Northwest by Blanke, C.D., Leblanc, M., Hershman, D., Meyskens, F., Taylor, L., Ellis, L.M.

Get full text

A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices by Pisters, P.W.T., Blanke, C.D., von Mehren, M., Picus, J., Sirulnik, A., Stealey, E., Trent, J.C.

“…The objective of the study was to describe patterns of care of patients with gastrointestinal stromal tumors (GISTs) in the United States in the tyrosine…”
Get full text

Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC) by Das, R., Ou, F., Washburn, C., Innocenti, F., Nixon, A., Lenz, H., Blanke, C., Niedzwiecki, D., Khalil, I., Harms, B., Venook, A.

Get full text

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030) by Louie, S G, Ely, B, Lenz, H-J, Albain, K S, Gotay, C, Coleman, D, Raghavan, D, Shields, A F, Gold, P J, Blanke, C D

“…Background: The aging process is accompanied by physiological changes including reduced glomerular filtration and hepatic function, as well as changes in…”
Get full text

Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC) by Das, R K, Furchtgott, L, Ou, F-S, Swanson, D, Hayete, B, Harms, B, Cunha, D, Latourelle, J, Wuest, D, Khalil, I, Washburn, C, Rich, K, Blanke, C D, Meyerhardt, J, Niedzwiecki, D, Nixon, A, O'Reilly, E M, Innocenti, F, Lenz, H-J, Venook, A

Get full text

Tyrosine Kinase Inhibitors Significantly Improved Survival Outcomes in Patients with Metastatic Gastrointestinal Stromal Tumour: A Multi-Institutional Cohort Study by Tan, A. Deruchie, Willemsma, K., MacNeill, A., DeVries, K., Srikanthan, A., McGahan, C., Hamilton, T., Li, H., Blanke, C.D., Simmons, C.E.

“…Background: The real-world impact of tyrosine kinase inhibitors (tkis) in clinical practice for gastrointestinal stromal tumour (gist) has not been extensively…”
Get full text

Progress and Infrastructure for Improved Patient Outcomes of the National Cancer Institute Network Groups by Blanke, C.D., MD, FACP, FASCO, Curran, Walter J., MD

Get full text

2007 A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405 by Innocenti, F, Owzar, K, Chen, J, Sibley, A, Niedzwiecki, D, Bertagnolli, M, Friedman, P, Furukawa, Y, Kubo, M, Ratain, M, Blanke, C, Heinz-Josef, L, Venook, A, McLeod, H

Get full text

1609 Final results from PAVES, a phase 3, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab for locally advanced or metastatic colorectal cancer (LA/mCRC) (NCT00911170) by Pinter, T, Morrow, P.K, Cesas, A, Croitoru, A, Decaestecker, J, Gibbs, P, Hotko, Y, Jassem, J, Kurteva, G, Novotny, J, O'Reilly, S, Salek, T, Khosrowshahi, L, Reiner, M, Klippel, Z, Blanke, C

Get full text

Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer by Blanke, C. D., Beer, T. M., Todd, K., Mori, M., Stone, M., Lopez, C.

“…Summary Purpose: To determine the safety and efficacy of weekly high-dose oral calcitriol and docetaxel, given to patients with non-resectable, incurable…”
Get full text

Calgb/Swog 80405: Analysis of Patients Undergoing Surgery As Part of Treatment Strategy by Venook, A., Niedzwiecki, D., Lenz, H., Mahoney, M., Innocenti, F., O'Neil, B., Hochster, H., Goldberg, R., Schilsky, R., Mayer, R., Polite, B., Atkins, J., Shaw, J.E., Bertagnolli, M., Blanke, C.

Get full text

Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer by Kennecke, H, Chen, L, Blanke, C D, Cheung, W Y, Schaff, K, Speers, C

“…The survival benefit for single-agent anti-epidermal growth factor receptor (egfr) therapy compared with combination therapy with irinotecan in KRAS wildtype…”
Get full text

Benefits, issues, and recommendations for personalized medicine in oncology in Canada by Butts, C, Kamel-Reid, S, Batist, G, Chia, S, Blanke, C, Moore, M, Sawyer, M B, Desjardins, C, Dubois, A, Pun, J, Bonter, K, Ashbury, F D

“…The burden of cancer for Canadian citizens and society is large. New technologies have the potential to increase the use of genetic information in clinical…”
Get full text

Epidemiology of GIST by Blanke, Charles, Eisenberg, Burton L, Heinrich, Michael

Get full text

9404 ORAL Long-term Survival on S0033 – a Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumours (GISTs) by Blanke, C, Rankin, C, Benjamin, R.S, Raymond, A.K, Heinrich, M.C, Fletcher, C.D.M, Crowley, J, Borden, E.C, Demetri, G.D, Baker, L.H

Get full text

A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma by Blanke, C. D., Haller, D. G., Benson, A. B., Rothenberg, M. L., Berlin, J., Mori, M., Hsieh, Y.-Ch, Miller, L. L.

“…Summary Background A phase II study testing the safety and efficacy of innotecan (CPT-11), 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in…”
Get full text